NASDAQ:CVRX CVRx (CVRX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free CVRX Stock Alerts $14.40 +0.11 (+0.77%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$14.03▼$14.5950-Day Range$14.29▼$23.2052-Week Range$9.18▼$33.13Volume119,882 shsAverage Volume113,133 shsMarket Capitalization$310.90 millionP/E RatioN/ADividend YieldN/APrice Target$33.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get CVRx alerts: Email Address CVRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside133.8% Upside$33.67 Price TargetShort InterestBearish8.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingSelling Shares$151,903 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.03 out of 5 starsMedical Sector541st out of 907 stocksSurgical & Medical Instruments Industry61st out of 96 stocks 3.5 Analyst's Opinion Consensus RatingCVRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCVRx has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.92% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in CVRx has recently increased by 6.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCVRx does not currently pay a dividend.Dividend GrowthCVRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVRX. Previous Next 1.9 News and Social Media Coverage News SentimentCVRx has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CVRx this week, compared to 2 articles on an average week.Search Interest5 people have searched for CVRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CVRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CVRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,903.00 in company stock.Percentage Held by Insiders18.30% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CVRx are expected to grow in the coming year, from ($1.89) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CVRx is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CVRx is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCVRx has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About CVRx Stock (NASDAQ:CVRX)CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More CVRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVRX Stock News HeadlinesApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and CVRx (CVRX)April 16, 2024 | finance.yahoo.comCVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024April 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | globenewswire.comCVRx announces availability of additional data supporting long-term benefits of BarostimApril 15, 2024 | globenewswire.comCVRx announces availability of additional data supporting long-term benefits of BarostimMarch 28, 2024 | fool.comWhat Companies Does Johnson & Johnson Own?March 21, 2024 | bizjournals.comTarget to double bonuses for salaried employees in signal of profit growthMarch 18, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Hold Rating on ProSomnus (OSA)April 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 25, 2024 | msn.comCVRx (CVRX) Price Target Increased by 10.54% to 33.15February 17, 2024 | finance.yahoo.comCVRX Mar 2024 30.000 callFebruary 17, 2024 | finance.yahoo.comCVRX Mar 2024 20.000 putFebruary 2, 2024 | finance.yahoo.comCVRx names Kevin Hykes as CEOFebruary 1, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on CVRx (CVRX)February 1, 2024 | msn.comCVRx Names Kevin Hykes as New President and CEOJanuary 31, 2024 | finance.yahoo.comCVRx Full Year 2023 Earnings: EPS Beats ExpectationsJanuary 31, 2024 | finanznachrichten.deCVRx, Inc.: CVRx Announces Appointment of Kevin Hykes as President and Chief Executive OfficerJanuary 31, 2024 | marketwatch.comCVRx Names Board Member Kevin Hykes President, CEOJanuary 31, 2024 | finance.yahoo.comCVRx Announces Appointment of Kevin Hykes as President and Chief Executive OfficerJanuary 31, 2024 | markets.businessinsider.comBio-Techne (TECH) Receives a Buy from Craig-HallumJanuary 28, 2024 | finance.yahoo.comCVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call TranscriptJanuary 26, 2024 | finanznachrichten.deCVRx, Inc.: CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsJanuary 26, 2024 | finance.yahoo.comQ4 2023 CVRx Inc Earnings CallJanuary 25, 2024 | benzinga.comCVRx: Q4 Earnings InsightsJanuary 25, 2024 | finance.yahoo.comCVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsJanuary 25, 2024 | finance.yahoo.comCVRx Inc (CVRX) Reports Substantial Revenue Growth in 2023January 24, 2024 | benzinga.comEarnings Outlook For CVRxSee More Headlines Receive CVRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CVRX CUSIPN/A CIK1235912 Webwww.cvrx.com Phone763-416-2840Fax763-416-2841Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$33.67 High Stock Price Target$36.00 Low Stock Price Target$32.00 Potential Upside/Downside+133.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-104.85% Pretax Margin-104.47% Return on Equity-47.30% Return on Assets-35.88% Debt Debt-to-Equity Ratio0.38 Current Ratio14.25 Quick Ratio12.86 Sales & Book Value Annual Sales$39.29 million Price / Sales7.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book3.95Miscellaneous Outstanding Shares21,590,000Free Float17,643,000Market Cap$310.90 million OptionableOptionable Beta1.29 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Kevin Hykes (Age 58)President, CEO & Director Mr. Jared Oasheim (Age 40)Chief Financial Officer Comp: $446.1kMr. Paul Verrastro (Age 61)Chief Marketing & Strategy Officer Comp: $529.84kMr. Paul PignatoVice President of OperationsMs. Jonelle R. Burnham (Age 53)Vice President & General Counsel Mr. Craig Palmer (Age 47)Senior Vice President of US Sales More ExecutivesKey CompetitorsLyra TherapeuticsNASDAQ:LYRACerusNASDAQ:CERSFractyl HealthNASDAQ:GUTSPulmonxNASDAQ:LUNGSanara MedTechNASDAQ:SMTIView All CompetitorsInsiders & InstitutionsGSG Advisors LLCSold 125,500 shares on 4/11/2024Ownership: 0.167%Paul VerrastroSold 2,545 sharesTotal: $55,760.95 ($21.91/share)& Johnson JohnsonSold 3,725 sharesTotal: $96,142.25 ($25.81/share)Parkman Healthcare Partners LLCBought 17,880 shares on 2/15/2024Ownership: 1.147%Tower Research Capital LLC TRC Sold 2,030 shares on 2/13/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions CVRX Stock Analysis - Frequently Asked Questions Should I buy or sell CVRx stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CVRX shares. View CVRX analyst ratings or view top-rated stocks. What is CVRx's stock price target for 2024? 3 analysts have issued twelve-month price targets for CVRx's stock. Their CVRX share price targets range from $32.00 to $36.00. On average, they predict the company's stock price to reach $33.67 in the next year. This suggests a possible upside of 133.8% from the stock's current price. View analysts price targets for CVRX or view top-rated stocks among Wall Street analysts. How have CVRX shares performed in 2024? CVRx's stock was trading at $31.44 at the beginning of the year. Since then, CVRX shares have decreased by 54.2% and is now trading at $14.40. View the best growth stocks for 2024 here. When is CVRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our CVRX earnings forecast. How can I listen to CVRx's earnings call? CVRx will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were CVRx's earnings last quarter? CVRx, Inc. (NASDAQ:CVRX) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.08. The firm had revenue of $3.40 million for the quarter, compared to analysts' expectations of $3.42 million. CVRx had a negative trailing twelve-month return on equity of 47.30% and a negative net margin of 104.85%. What ETF holds CVRx's stock? iShares Neuroscience and Healthcare ETF holds 717 shares of CVRX stock, representing 0.32% of its portfolio. What guidance has CVRx issued on next quarter's earnings? CVRx updated its first quarter 2024 earnings guidance on Friday, January, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.0 million-$12.0 million, compared to the consensus revenue estimate of $11.6 million. When did CVRx IPO? CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are CVRx's major shareholders? CVRx's stock is owned by a number of retail and institutional investors. Top institutional investors include GSG Advisors LLC (0.17%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Mudit K Jain, Nea Partners 10 L P and Paul Verrastro. View institutional ownership trends. How do I buy shares of CVRx? Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CVRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
